The role of pharmacotherapy in the treatment of chronic thromboembolic pulmonary hypertension (RCD code: II-1A.5)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 2
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease caused by chronic obstruction of major pulmonary arteries. The median age of patients at diagnosis of CTEPH is 63 years and both genders are equally affected. The symptoms are usually nonspecific, particularly in the early stages of the disease, which significantly delays the diagnosis. All patients with pulmonary hypertension (PH) of the unknown aetiology should be diagnosed for CTEPH, even without the information on pulmonary embolism in the medical history. Ventilation-perfusion scintigraphy of the lungs has the highest sensitivity in the diagnosis of CTEPH. A positive result of scintigraphy suggestive of CTEPH is not enough to diagnose the disease. Right heart catheterization and angiography of the pulmonary arteries definitively confirm the diagnosis. All patients with CTEPH should receive chronic oral anticoagulation using generally vitamin K antagonists (warfarin, acenocumarol). Pulmonary endarterectomy (PEA) is the only effective treatment for eliminating the cause of the disease. However, not all patients can be referred for pulmonary endarterectomy surgery. According to data from the European CTEPH Registry of the years 2007-2009, over 40% of patients is not subjected to the operation mainly due to the distal location of thromboembolic changes. Currently, riociguat is the only approved therapeutic agent for the pharmacological treatment of inoperable/persistent CTEPH. In some cases, Off-lebel use of drugs approved for PAH may be considered in symptomatic patients with inoperable CTEPH/persistent PH after PEA. Recent advances in balloon pulmonary angioplasty make it a promising therapeutic alternative for selected patients with non-operable CTEPH. JRCD 2015; 2 (2): 4–8
Authors and Affiliations
Barbara Widlińska, Grzegorz Kopeć, Piotr Podolec
Keywords
Related Articles
- EP ID EP245454
- DOI 10.20418/jrcd.vol2no2.164
- Views 88
- Downloads 0
Isolated right ventricular endomyocardial fibrosis in a young male with chronic myeloid leukemia (RCD code: III‑3F.2)
Endomyocardial fibrosis (EMF) is a rare disease of unknown etiology which is more prevalent in tropical countries. EMF is associated with fibrosis of endomyocardium, involving one or both ventricles. It usually presents...
JRCD is now included in the J‐Gate database, Free Medical Journals list, and JournalTOCs
We present to you the first issue of Journal of Rare Cardiovascular Diseases (JRCD) for 2018.
Long QT syndrome diagnosed in the postpartum period (RCD code: VII-V-1A.2)
We report a case of 22 years old woman with long QT syndrome type with the first cardiac incidents in the post partum period. We discuss the actual treatment recommendation in the long QT syndrome with special attention...
Update on myocarditis – review (RCD code: III-6A.1)
Myocardits is an inflammatory disease of the myocardium diagnosed by established histological and immunohistochemical criteria. The true incidence of myocarditis is unknown. There are numerous potential etiologic factors...
Journal of Rare Cardiovascular Diseases: “One finger cannot lift a pebble” – cooperation as the only way to move forward
Dear Readers,Gaining more experience and exchange of knowledge in one thing is the only way to advance the field of rare cardiovascular diseases (RCD). Taking care of RCD patients on a daily basis quickly leads to realiz...